Pimea AI

A personalized healthcare app (mHealth) for allergies that accesses the subconscious mind to retrain the immune system to avoid, or reduce, allergy inflammation for a long period

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in June 2022 by Omer Hevlin, Pimea AI operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a digital personalized healthcare therapy for allergies.

Business overview

Pimea AI is developing a digital personalized healthcare therapy designed to revolutionize the global allergy industry. The company's core technology utilizes advanced algorithms to analyze patients' physiological parameters and autonomously administer a proprietary therapeutic protocol. This protocol accesses the subconscious mind to retrain the immune system, aiming to avoid or reduce allergy inflammation for extended periods. Pimea AI serves the healthcare market, targeting both B2C and B2B2C models, and operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Therapeutics.

Company Intelligence Q&A

What is Pimea AI's primary focus?: Pimea AI focuses on developing a personalized digital healthcare therapy for allergies, aiming to retrain the immune system to reduce or avoid allergy inflammation.
When was Pimea AI founded?: Pimea AI was founded in June 2022.
Who is the founder of Pimea AI?: Omer Hevlin is the Founder & CEO of Pimea AI.
What markets does Pimea AI target?: Pimea AI targets global markets, with a specific focus on North America.
What is the current product stage for Pimea AI?: Pimea AI's product, Pimea Allergy, is currently in the Research & Development (R&D) stage.

External links

Pimea AI — full profile (machine-readable)

A steady increase in the prevalence of allergic diseases globally has occurred with about 30-40% of the world population now being affected by one or more allergic conditions. Modern healthcare bodies and authorities agree that they cannot cure an allergy, but can only treat the symptoms by either avoiding the allergen, taking medications (Antihistamines and Steroids, epinephrine (EpiPen)), or getting into a long-lasting treatment process of 2-4 years, called Immunotherapy. We are developing a digital personalized healthcare therapy that will revolutionize the global allergy industry and the a/m concept by offering a nonintrusive solution that leverages decades of impactful alternative medicine therapies and techniques to overcome allergies. Our solution utilizes advanced algorithms that analyze patients' physiological parameters to autonomously administer a proprietary therapeutic protocol that by accessing the subconscious mind retrains the immune system to avoid, or reduce, allergy inflammation for a long period, which means developing resilience to the disease and prevent allergy symptoms for an extended period. Our methodology is firmly rooted in the modern holistic healthcare paradigm, which seamlessly integrates conventional medicine with complementary and alternative practices. The treatment, a quick 20- to 30-minute session, can be seamlessly integrated into mainstream healthcare or employed as a standalone therapy. Drawing inspiration from the scientific field of psychoneuroimmunology, our treatments address each patient's mental state and mindset. Pimea AI is committed to ushering in a new era of allergy relief that prioritizes individual well-being and long-term health.

Facts
Name	Pimea AI
One-liner	A personalized healthcare app (mHealth) for allergies that accesses the subconscious mind to retrain the immune system to avoid, or reduce, allergy inflammation for a long period
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2022
Employees	1-10
Employees (exact)	3
HQ / location	Tel Aviv-Yafo, Tel Aviv-Yafo, Israel, Center District
Product stage	R&D
Website	https://pimea-ai.com/

Facts

Name

Pimea AI

One-liner

A personalized healthcare app (mHealth) for allergies that accesses the subconscious mind to retrain the immune system to avoid, or reduce, allergy inflammation for a long period

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2022

Employees

1-10

Employees (exact)

HQ / location

Tel Aviv-Yafo, Tel Aviv-Yafo, Israel, Center District

Product stage

R&D

Website

https://pimea-ai.com/

Classification
Sectors	Health Tech & Life Sciences, Digital Healthcare, Digital Therapeutics, Medical Devices, Medical Treatment & Therapeutics
Core technology	Sensing, Platforms & Interfaces, Software, Artificial Intelligence
Target customers	Consumers, Healthcare & Life Sciences, Healthcare, Providers, Patients
Business models	B2C, B2B2C, B2B
Tags	healthcare-providers, algorithms, personalized-treatment, chronic-patients, autoimmune-diseases, immunology, digital-therapeutics, digital-healthcare, software-applications, allergy, non-invasive, treatments, artificial-intelligence, data-analytics, neurology, clinics, pharma-companies, machine-learning

Classification

Sectors

Health Tech & Life Sciences, Digital Healthcare, Digital Therapeutics, Medical Devices, Medical Treatment & Therapeutics

Core technology

Sensing, Platforms & Interfaces, Software, Artificial Intelligence

Target customers

Consumers, Healthcare & Life Sciences, Healthcare, Providers, Patients

Business models

B2C, B2B2C, B2B

Pimea AI

Company Overview

Snapshot

Business overview

Company Intelligence Q&A

External links

Generate Slim Page